Kyowa Kirin expects top-line ProStrakan benefits this year
This article was originally published in Scrip
Kyowa Hakko Kirin expects its new acquisition ProStrakan to add ¥7.4 billion ($94.8 million) to its net pharma sales this year, although amortisation costs associated with the now completed £292 million deal will dampen operating profit.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.